TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07220915: Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Sponsor: Octapharma · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$832,830

Rescue Site Savings

+$538,890

Unlock Full NCT07220915 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07220915 Rescue Dossier →